PRMT5

Notes

original target text: PRMT5 inhibitor

Protein arginine methyltransferase 5 (PRMT5) is an enzyme that adds methyl groups to arginine residues on histone proteins and many other cellular proteins, thereby influencing gene transcription, RNA splicing, and DNA damage repair. Because PRMT5 activity supports the proliferation of many cell types, particularly rapidly dividing cancer cells, its enzymatic function has become a target for pharmacological inhibition. A key biological rationale for this approach centers on tumors that carry deletion of the neighboring gene MTAP, which is frequently co-deleted with a tumor suppressor locus in several solid tumors. Loss of MTAP causes accumulation of a metabolite that partially inhibits PRMT5, creating a dependency state in which further pharmacological suppression of PRMT5 selectively harms MTAP-deleted cancer cells while sparing normal tissue that retains MTAP. This concept, known as synthetic lethality, underlies interest in PRMT5 inhibitors as a way to achieve a therapeutic window in an epigenetic target that would otherwise be broadly essential and difficult to inhibit safely. Small-molecule inhibitors of PRMT5 are being explored primarily in oncology, with particular relevance to cancers defined by this specific genetic deletion, illustrating a broader strategy of exploiting tumor-specific metabolic vulnerabilities rather than targeting a pathway unique to cancer cells alone.